Integra Lifesciences Holdings (STU:IL3) LT-Debt-to-Total-Asset: 0.56 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IL3 Integra Lifesciences Holdings Corp STU:IL3
74 GF Score
Price €16.40
GF Value €20.79
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings LT-Debt-to-Total-Asset?

Integra Lifesciences Holdings STU:IL3 +2.50% 74 LT-Debt-to-Total-Asset is 0.56 as of Mar. 2026. GuruFocus rates STU:IL3 with a GF Score™ of 74/100 and a GF Value™ of €20.79 (Modestly Undervalued). The stock has 11 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Integra Lifesciences Holdings's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.56.

Integra Lifesciences Holdings's long-term debt to total assets ratio increased from Mar. 2025 (0.34) to Mar. 2026 (0.56). It may suggest that Integra Lifesciences Holdings is progressively becoming more dependent on debt to grow their business.

Integra Lifesciences Holdings  (STU:IL3) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Related Terms

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Integra Lifesciences Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Chart

Integra Lifesciences Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.40 0.44 0.34 0.53

Integra Lifesciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.38 0.54 0.53 0.56
STU:IL3
74GF Score
Integra Lifesciences Holdings Corp STU:IL3
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integra Lifesciences Holdings LT-Debt-to-Total-Asset Calculation

Integra Lifesciences Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=1616.293/3076.109
=0.53

Integra Lifesciences Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=1718.557/3094.733
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.56 mean?
Integra Lifesciences Holdings (STU:IL3) has a LT-Debt-to-Total-Asset of 0.56 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Integra Lifesciences Holdings and its competitors.
Is Integra Lifesciences Holdings' LT-Debt-to-Total-Asset too high?
Integra Lifesciences Holdings' current LT-Debt-to-Total-Asset is 0.56. Overall, Integra Lifesciences Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' LT-Debt-to-Total-Asset compare to ATEC and AHCO?
Integra Lifesciences Holdings' LT-Debt-to-Total-Asset of 0.56 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Integra Lifesciences Holdings and its competitors. Integra Lifesciences Holdings's current LT-Debt-to-Total-Asset is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (STU:IL3) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.79, compared to a current price of €16.40 — trading 21.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.56. Integra Lifesciences Holdings' overall GF Score™ is 74/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Integra Lifesciences Holdings (STU:IL3), the current LT-Debt-to-Total-Asset is 0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of €16.40 is trading 21.1% below its estimated GF Value™ of €20.79. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for STU:IL3:

  • LT-Debt-to-Total-Asset: 0.56
  • GF Value™: €20.79 vs. price of €16.40 (21.1% below fair value)
  • GF Score™: 74/100 with 11 warning signs

No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integra Lifesciences Holdings Business Description

Other Exchanges IART:USA
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score

Get the complete analysis for STU:IL3

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.40
Price
€20.79
GF Value